drugset / Trial / NCT00711074

Mass Balance and Metabolic Profiling of [14C]AZD5672 in Healthy Male Volunteers

NCT00711074

Phase 1 Completed 4 enrolled AstraZeneca
NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine how the body breaks down and excretes the investigational drug, AZD5672.

Timeline

Start
2008-06
Primary completion
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5672 Small molecule 200 mg

Indications